Bone Marrow Transplant Clinical Trial
Official title:
Technology-assisted, In-home Remote Patient Monitoring, Telemedicine, and Home-based Health Care for Treatment of Bone Marrow Transplant Patients.
Verified date | December 2022 |
Source | University of Colorado, Denver |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study is designed to assess the potential for successfully using technology-assisted in-home oncology care, including remote patient monitoring (RPM), telemedicine, and home-based health care services to support improved care management and appropriate referral to treatment for bone marrow transplant (BMT) patients.
Status | Completed |
Enrollment | 10 |
Est. completion date | October 16, 2022 |
Est. primary completion date | October 16, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 89 Years |
Eligibility | Inclusion Criteria: - Age 18 years to 89 years old - Bone marrow transplant recipients (allogeneic) - Determined by care provider to be stable for discharge to home setting for outpatient care according to clinical practice standard operating procedures (SOPs) - Residing in the Denver metro area for the duration of the study within 45 minutes of the AMC - Has in-home caregiver support 24/7 (i.e., does not live alone) - Has reliable telephone and home internet service and stable wireless network - Patient has agreed to not submerge the BioSticker device in more than 3 feet of water or submerge for longer than 30 minutes at a time. - Patient owns or possesses, as the primary user with reliable daily access, a mobile device (iOS or Android) capable of running the study's mobile application and accepting the terms and conditions - Patient is willing to complete a self-check temperature log to comply and be available for the duration of the study - Has access to reliable transportation to the hospital 24/7 Exclusion Criteria: Patients will be excluded from study participation if the PI or designated care provider believes study participation would not be in the patient's best interest for clinical reasons. |
Country | Name | City | State |
---|---|---|---|
United States | University of Colorado Hospital | Aurora | Colorado |
Lead Sponsor | Collaborator |
---|---|
University of Colorado, Denver | Reimagine Care |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Cost of service provision | in US dollars. | Up to 90 days | |
Other | Days in hospital in first 90 day post-transplant | In days | Up to 90 days | |
Other | Length of hospital stay | In days | Up to 90 days | |
Other | Number of ICU admissions post-transplant | Number of ICU admissions | Up to 90 days | |
Other | Death rates associated with admission for febrile neutropenia | Number of | Up to 90 days | |
Primary | Number of patients without infection | Number of patients managed at home while using device who did not have an infection. This measure is collected for comparison with alerts. The device does not prevent infection. | Up to 90 days | |
Primary | Number of alerts detected through RPM | Alert frequency is tracked to evaluate device function for feasibility of use in the clinical workflow. Patient treatment is not alert-based and is dependent on independent clinical confirmation. An alert of interest is defined as any of the following:
Oral temperature greater than or equal to 100.4 F (38.0 C) for 1 hour or one reading of 101 F (38.33C); Mean skin temperature over 1 hour > 98.5 F (36.9 C) or 2.5 times standard deviation from patient's baseline over 1 hour; Mean heart rate over 1 hour > 120 beats per minute or 30% overpatient's baseline over 1 hour Mean respiratory rate over 1 hour > 24 breaths per minute or 30% over patient's baseline over 1 hour, does not return to baseline following exertion; The "BioIntelliSense Infection-Like AlertSymptoms" alert will also be monitored. |
Up to 90 days | |
Primary | Number of patients with infection, but without need for hospitalization | Number with infection, without hospitalization, while using device, for comparison with alerts. | Up to 90 days | |
Primary | Number of patients with infection, with need for hospitalization | Number with infection, with hospitalization, while using device, for comparison with alerts. | Up to 90 days | |
Secondary | Patient satisfaction: Functional Assessment of Cancer Therapy-General (FACT-G) | The Functional Assessment of Cancer Therapy - General (FACT-G) is a 27-item questionnaire that measures Health-related quality of life (HRQoL) in cancer patients. Responses to each question are scored on a 5 point likert scale ranging from 0 (Not at all) to 4 (Very much). Possible total scores range from 0-108, with higher scores indicating a better outcome/better QoL. | Baseline | |
Secondary | Transplant Evaluation Rating Scale (TERS) | The Transplant Evaluation Rating Scale (TERS) measures the predicted impact of psychosocial factors on the successful outcome of transplant. The measurement consists of an expert interview, in which the assessor evaluates 10 distinct domains considered relevant to successful adjustment to the transplant, and rates responses from 1-3. These scores are then weighted for relevance to determine a total weighted score. Possible total scores range from 26.5 to 79.5, with higher scores indicating a worse outcome (greater impairment in psychosocial functioning). | Baseline | |
Secondary | Patient satisfaction: Functional Assessment of Cancer Treatment - Blood/Marrow Transplant (FACT-BMT) | The Functional Assessment of Cancer Treatment - Blood/Marrow Transplant (FACT-BMT) assesses quality of life in adult cancer patients undergoing blood & bone marrow transplant. The scale includes 5 subscales. The scores of each scale are summed to compute a total score. Possible total scores range from 0-148. Higher scores indicate a better quality of life and a better outcome. | Day 30, Day 90 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT02451462 -
Pilot Trial of Zoledronic Acid to Prevent Bone Loss in Hematopoietic Cell Transplant Recipients
|
N/A | |
Completed |
NCT03654599 -
Effects of Digital Stories Intervention on Psychosocial Well-being
|
N/A | |
Active, not recruiting |
NCT04395222 -
Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation
|
Phase 2 | |
Not yet recruiting |
NCT05603156 -
A Study of Olverembatinib Combined With Inotuzumab Ozogamicin in the Treatment ph+ ALL With MRD Persistent Positive
|
N/A | |
Completed |
NCT03530969 -
Geriatric Communication Skills Training Program for Oncology Clinicians
|
N/A | |
Recruiting |
NCT04115241 -
Activity Levels in Bone Marrow Transplant Patients
|
||
Completed |
NCT00143780 -
Pneumonia Vaccine in Bone Marrow Transplant Recipients: Usefulness of Donor Vaccination
|
Phase 4 | |
Completed |
NCT03028961 -
Stanford Letter or Traditional Advance Directive in Advance Care Planning in Patients Undergoing Bone Marrow Transplant
|
N/A | |
Completed |
NCT02575079 -
Parafilm to Prevent CLABSI in Pediatric Patients Undergoing HCT
|
N/A | |
Active, not recruiting |
NCT02665065 -
Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia
|
Phase 3 | |
Completed |
NCT01735565 -
Neutrophil Extracellular Trap Formation in Patients Undergoing Bone Marrow Transplant
|
N/A | |
Completed |
NCT04041219 -
Use of Sublingual Tacrolimus in Adult Blood and Marrow Transplant Patients
|
Phase 4 | |
Not yet recruiting |
NCT06361173 -
Spanish BMT4me Usability & Acceptability
|
||
Completed |
NCT03030248 -
Vancomycin for C Difficile NAAT+/EIA- Hematology Oncology Patients
|
Phase 2 | |
Completed |
NCT00695123 -
Screening for Subjects to Participate in Studies of Blood Disorders
|
||
Terminated |
NCT02057289 -
A Pharmacokinetic Study of Pediatric Micafungin Prophylaxis
|
Phase 1 | |
Completed |
NCT04275830 -
The Effects of Heart Rate Variability Biofeedback Training on Hematopoietic Cell Transplantation Patients
|
N/A | |
Completed |
NCT03902210 -
BMT Online Wellness Study
|
N/A | |
Completed |
NCT03245788 -
Effectiveness of Lay Navigators in Meeting Cancer Patients' Non-Clinical Needs: A Pilot Study
|
N/A | |
Completed |
NCT03758911 -
Perspectives on Bone Marrow Donors Who Donate for Their Parent
|